<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03807167</url>
  </required_header>
  <id_info>
    <org_study_id>35RC18_8833_ACTIDEP</org_study_id>
    <nct_id>NCT03807167</nct_id>
  </id_info>
  <brief_title>Apathy in Late Life Depression: New Biomarkers Using Actimetry and Magnetic Resonance Imaging</brief_title>
  <acronym>ACTIDEP</acronym>
  <official_title>Apathy in Late Life Depression: New Biomarkers Using Actimetry and Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Old age (&gt; 60 years) is at high risk to develop major depression disorders (MDD). MDD doubles
      the risk for subsequent cognitive disorders and dementia. Apathy (i.e. the lack of
      motivation) is a core problem in depression in older age and is frequently associated with
      cognitive decline in people who have mild cognitive disorders. The investigator propose here
      to combine actimetry (the measurement of motor activity using a simple device worn at the
      wrist) and brain imaging to show that it's possible to measure apathy using actimetry in a
      population of elders with MDD. Having shown that apathy can reliably be measured with
      actimetry and that it is associated with brain abnormalities, the investigator will be able
      to test whether actimetry can predict cognitive decline in elders with MDD and can be
      routinely used in a day-to-day medical practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Actimetry</measure>
    <time_frame>3 days</time_frame>
    <description>Measure of actimetry: immobility, transfer, walking, movement given by the accelerometer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>grey matter density</measure>
    <time_frame>at Day 3 (+/- 2 days)</time_frame>
    <description>Magnetic Resonance Imaging brain metrics: grey matter density</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cortical thickness</measure>
    <time_frame>at Day 3 (+/- 2 days)</time_frame>
    <description>Magnetic Resonance Imaging brain metrics: cortical thickness;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diffusion tensor imaging,</measure>
    <time_frame>at Day 3 (+/- 2 days)</time_frame>
    <description>Magnetic Resonance Imaging brain metrics: diffusion tensor imaging,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rest functional connectivity analysis</measure>
    <time_frame>at Day 3 (+/- 2 days)</time_frame>
    <description>Magnetic Resonance Imaging brain metrics: regional cerebral blood flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulsatility.</measure>
    <time_frame>at Day 3 (+/- 2 days)</time_frame>
    <description>Magnetic Resonance Imaging brain metrics: pulsatility.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mattis Dementia Rating Scale</intervention_name>
    <description>This scale was developed to assess the cognitive status of patients with neurodegenerative diseases. There are 37 items that are presented in a fixed order and grouped into five sub-scales: attention, initiation, construction, conceptualization and memory. Patients and healthy subjects with a score below 125 are not included because of major cognitive impairment.</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Unified Parkinson 's Disease Rating Scale-III</intervention_name>
    <description>This scale is used to rate the severity of extra-pyramidal symptoms (akinesia, rigidity and tremors). These symptoms may be the cause of reduction of motor activity apart from any reduction in motivation, they onstitute a confounding factor that it should be controlled.</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mini Neuropsychiatric Investigation</intervention_name>
    <description>This is a structured interview that allows rapid screening in about 20 minutes of troubles Psychiatric. It is based on short questions to which the patient must answer yes or no and on a decision tree. Patients must validate clinical diagnoses of depression.</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Montgomery and Asberg depression Rating Scale</intervention_name>
    <description>This scale is composed of 10 items from 0 to 6 from a semi-structured interview, to obtain a total depression score of 0 to 60 (0 no depression, 60 maximum intensity of depression).</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical Global Impression</intervention_name>
    <description>heterosexual assessment that rates the severity of symptoms suicidal and changes in suicidal symptoms. Any subject with a score greater than 4 is not included.</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Apathy diagnostic criteria</intervention_name>
    <description>The clinical criteria make it possible to make a diagnosis of apathy with a functional repercussion. It is based on a lack of motivation felt by the patient, causing a functional or social impact that is not the consequence of a disturbance of consciousness or a disability engine. The cognitive, emotional and behavioral dimensions are affected.</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>walking speed test</intervention_name>
    <description>The patient is timed to walk 10m. A speed &lt;1m / sec is a criterion exclusion because it shows severe sarcopenia and constitutes a bias.</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>accelerometer presentation</intervention_name>
    <description>accelerometer presentation and pose</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data acquisition from the accelerometer</intervention_name>
    <description>withdrawal of the accelerometer and data acquisition from the accelerometer</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Apathy Evaluation Scale,</intervention_name>
    <description>clinician version and near-helping version. It's a hetero rating scale from an interview semi structured by a trained clinician. It assesses cognitive, emotional and behavioral apathy than three items of various apathy. The total score ranges from 18 (total absence of apathy) to 72.</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fatigue Visual Analog Scale</intervention_name>
    <description>To date, there is no valid fatigue scale in the depression of the elderly subject, a fortiori in French. The fatigue scale in adult depression includes has been validated with an EVA (Visual Analogue Scale) (38). We therefore propose to use this type of evaluation to control this aspect.</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>executive function</intervention_name>
    <description>Modified Card Sorting Test MCST(Modified Card Sorting Test) (Wisconsin Test): This test assesses conceptualization, attention and mental flexibility using a deck of cards.
Trail Making Test (TMT): This test is used to assess mental flexibility.
Fluences verbal: This test tests the capacities of setting up search strategies in memory semantics and oral language.
Stroop Paradigm: This test is used to evaluate the resistance to interference, ie the patient's ability to inhibit some over-learned and automated responses.</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>An MRI lasting 30 minutes is programmed</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Apathy Motivation Index</intervention_name>
    <description>This is a self-questionnaire of 18 items, each side on a 5-level Likert scale (0: not everything at 4: very often). It differentiates between &quot;behavioral&quot; apathy and &quot;social&quot; apathy.
&quot;Emotional&quot;.</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients:

          -  60 years and above

          -  Major depressive disorder (either late-onset or early onset)

          -  Ambulatory settings

          -  Both uni and bipolar depression will be considered Healthy controls

          -  60 years and above

          -  No psychiatric disorders, including no major depressive disorder

          -  No non-inclusion criteria

        Exclusion Criteria:

          -  Patients and healthy controls

          -  Major cognitive disorders (&lt; 125 on the Mattis dementia rating scale and a major
             cognitive disorders diagnostic according to the DSM5 (Diagnostic and Statistical
             Manual of Mental Disorders) criteria).

          -  Other neurological conditions (stroke, Parkinson's disease and seizures), severe and
             inflammatory disorders (ex: severe arthroses which limits movements, spondylarthritis)

          -  Severe sarcopenia: speed walk &lt; 1 meter/second

          -  Extrapyramidal syndrome

          -  High suicidal risk

          -  Anti-psychotic prescription

          -  Participant who are unable to provide clear consent, under legal protection

          -  MRI contra-indication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gabriel Robert</last_name>
    <phone>02.99.33.39.37</phone>
    <email>gabriel.hadrien.robert@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Mémoire de Ressources et de Recherche (CMRR),</name>
      <address>
        <city>Nice</city>
        <zip>06100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud David</last_name>
    </contact>
    <investigator>
      <last_name>Renaud David</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou, Département de Radiologie et d'Imagerie Médicale</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe FERRE</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Christophe FERRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Robert</last_name>
      <phone>02.99.33.39.37</phone>
      <email>gabriel.hadrien.robert@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gabriel Robert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau, Consultations Intersectorielles de Gérontopsychiatrie</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas DESMIDT</last_name>
      <phone>02 34 37 89 52</phone>
    </contact>
    <investigator>
      <last_name>Thomas DESMIDT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau,CIC</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Gissot</last_name>
    </contact>
    <investigator>
      <last_name>Valérie Gissot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Radiologie- Neuroradiologie,CHU bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe Cottier</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Philippe Cottier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 7, 2018</study_first_submitted>
  <study_first_submitted_qc>January 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 16, 2019</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

